期刊
NATURE MICROBIOLOGY
卷 5, 期 10, 页码 1185-1191出版社
NATURE PORTFOLIO
DOI: 10.1038/s41564-020-00789-5
关键词
-
类别
资金
- Victorian government
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology
- Australian National Health and Medical Research Council (NHMRC) programme [1149990]
- NHMRC [1162760]
- United States National Institutes of Health [1DP5OD023118, R21AI143407]
- COVID-19 Fast Grants programme
- Jack Ma Foundation
- National Health and Medical Research Council of Australia [1162760] Funding Source: NHMRC
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2. Mechanisms of antibody-dependent enhancement of disease and mitigation strategies for SARS-CoV-2 vaccines and therapies are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据